DMAC vs. KMPH, ESPR, SLRN, TBPH, PGEN, CTNM, BMEA, TERN, VRCA, and NLTX
Should you be buying DiaMedica Therapeutics stock or one of its competitors? The main competitors of DiaMedica Therapeutics include Zevra Therapeutics (KMPH), Esperion Therapeutics (ESPR), Acelyrin (SLRN), Theravance Biopharma (TBPH), Precigen (PGEN), Contineum Therapeutics (CTNM), Biomea Fusion (BMEA), Terns Pharmaceuticals (TERN), Verrica Pharmaceuticals (VRCA), and Neoleukin Therapeutics (NLTX). These companies are all part of the "pharmaceutical preparations" industry.
Zevra Therapeutics (NASDAQ:KMPH) and DiaMedica Therapeutics (NASDAQ:DMAC) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, valuation, institutional ownership, earnings, analyst recommendations, dividends, community ranking, profitability and media sentiment.
19.4% of Zevra Therapeutics shares are held by institutional investors. Comparatively, 10.1% of DiaMedica Therapeutics shares are held by institutional investors. 1.1% of Zevra Therapeutics shares are held by insiders. Comparatively, 7.2% of DiaMedica Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
DiaMedica Therapeutics has a consensus price target of $7.00, suggesting a potential upside of 169.23%.
Zevra Therapeutics received 255 more outperform votes than DiaMedica Therapeutics when rated by MarketBeat users. Likewise, 62.96% of users gave Zevra Therapeutics an outperform vote while only 62.07% of users gave DiaMedica Therapeutics an outperform vote.
DiaMedica Therapeutics has a net margin of 0.00% compared to DiaMedica Therapeutics' net margin of -328.56%. DiaMedica Therapeutics' return on equity of -16.12% beat Zevra Therapeutics' return on equity.
Zevra Therapeutics has higher revenue and earnings than DiaMedica Therapeutics.
Zevra Therapeutics has a beta of 2.16, suggesting that its share price is 116% more volatile than the S&P 500. Comparatively, DiaMedica Therapeutics has a beta of 1.74, suggesting that its share price is 74% more volatile than the S&P 500.
In the previous week, DiaMedica Therapeutics' average media sentiment score of 0.00 equaled Zevra Therapeutics'average media sentiment score.
Summary
Zevra Therapeutics beats DiaMedica Therapeutics on 8 of the 11 factors compared between the two stocks.
Get DiaMedica Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for DMAC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding DMAC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
DiaMedica Therapeutics Competitors List
Related Companies and Tools
